Natural History of Gastric Cancer: Observational Study of Gastric Cancer Patients Not Treated During Follow-Up

188 Background: Gastric cancer is highly prevalent amongst men and women. While many studies have identified the prevalence and association of iron deficiency anemia (IDA) in all cancer patients, few have focused on the gastric cancer population. The primary objective of this study was to determine the proportion of patients with gastric cancer who developed IDA, and chemotherapy induced anemia (CIA) at our institution. Secondary objectives were to identify types and frequencies of IDA therapies used. Methods: A retrospective study was carried out in 110 consecutive gastric cancer patients from 2006 to 2014 at St. Michael’s Hospital, Toronto, Canada. Patient demographics, previous history of IDA, and IDA based therapies were reviewed. IDA was defined as hemoglobin (Hb) < 130 g/L in men and < 120g/L in women and iron deficiency (ID) was defined as a ferritin < 15m/L. SAS 9.3 was used to calculate frequencies and proportions. Results: Of the 110 patients (median age 68.5 [interquartile range (IQR): 58-76]), 72 (65%) were male. Most patients were diagnosed at stage IV (35%) with a mean Hb of 118 g/L (standard deviation (SD): 19.7 g/L). Only 18 (16%) patients had a history of IDA prior to cancer diagnosis, and 63 (57%) had IDA at time of gastric cancer diagnosis. Only 29 patients (45%) had ferritin levels tested at first oncology visit. Of the 110 patients, 71 patients had an open (32%) or laparoscopic (68%) surgery. A total of 66 patients received chemotherapy, and 50 (76%) developed CIA. In this sample, 9 (14%) experienced a chemotherapy dose delay and 20 (30%) had a dose reduction. At last follow up, 87 (79%) of patients were diagnosed with IDA. Red blood cell (RBC) transfusions were most frequently prescribed (95%), compared to oral (29%) or intravenous iron (12%). Conclusions: A total of 87 (79%) gastric cancer patients were diagnosed with IDA and nearly all patients received a RBC transfusion. We found that the diagnosis of IDA increased by 22% from the time of gastric cancer diagnosis to last follow up. There was a high proportion of IDA in our gastric cancer population despite inconsistent screening for ID. This highlights the need for consistent screening and targeted therapy for ID to reduce transfusions and improve quality of life in this patient population.

Download Full-text

FOLLOW-UP STUDY OF GASTRIC CANCER PATIENTS WITH TUMOR INVASION AT THE CUT EDGE OF ORAL MARGIN

The Japanese Journal of Gastroenterological Surgery ◽

10.5833/jjgs.14.1409 ◽

1981 ◽

Vol 14 (10) ◽

pp. 1409-1413

Author(s):

Hideaki NISHIDOI ◽

Osamu KIMURA ◽

Tsuneyuki OKAMOTO ◽

Hideaki TAMURA ◽

Nobuaki KAIBARA ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Tumor Invasion ◽

Cut Edge ◽

Follow Up Study ◽

Gastric Cancer Patients

Download Full-text

The natural history of latent rheumatic heart disease in a 5 year follow-up study: a prospective observational study

BMC Cardiovascular Disorders ◽

10.1186/s12872-016-0225-3 ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 37

Author(s):

Liesl Zühlke ◽

Mark E. Engel ◽

Carolina E. Lemmer ◽

Marnie van de Wall ◽

Simpiwe Nkepu ◽

...

Keyword(s):

Heart Disease ◽

Natural History ◽

Observational Study ◽

Rheumatic Heart Disease ◽

Prospective Observational Study ◽

Follow Up Study ◽

History Of ◽

Rheumatic Heart

Download Full-text

The relationship between HER-2 and TOPO-2A gene expression and clinicopathologic results in gastric cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e14670 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e14670-e14670

Author(s):

Metin Ozkan ◽

Esra Ermis Turak ◽

Halit Karaca ◽

Mevlude Inanc ◽

Veli Berk ◽

...

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Median Overall Survival ◽

Intestinal Type ◽

Negative Group ◽

Diffuse Type ◽

Her 2 ◽

Gastric Cancer Patients

e14670 Background: HER-2 and Topo-2A genes are settled on a chromosome 17 and their co-amplification rates are high. In this study, early gastric cancer patients who received adjuvant chemo-radiotherapy and chemotherapy were evaluated with HER-2 and Topo-2A expression in association with clinical and histopathologic findings. Methods: A total of 103 gastric cancer patients were included the study. The HER-2 and Topo-2A levels were measured by immunohistochemistry in postoperative tumor materials. A standard evaluation method was admitted for HER-2 positivity, while Topo-2A nuclear staining 3+ and 4+ were considered as overexpression. Those with level 2+ or 3+ of HER-2, the FISH test were attempted. Results: The median follow-up was 19 months (ranges 2–70 months). Forty-six patients (44%) relapsed during follow-up whereas 60 patients (58%) had died. The median overall survival (mOS) was 23 months. Histopathologies of HER-2 positive patients were intestinal type in 7 (87.5%) and diffuse type in one (12.5%) patient. In the follow-up period 4 patients (50%) were died (mOS was 17 months in this group). Median overall survival was 23 months in HER-2 negative group (p=0.6). Histopathologies of Topo-2A positive patients were intestinal type in 9 (64.2%) and diffuse type in 5 (35.8%) patient. In the follow-up period 8 patients (57%) were died (mOS was 22 months in this group). Median overall survival was 23 months in Topo-2A negative group (p=0.8). Three patients (37.5%) who had HER-2 positive histopathologies also had Topo-2A positivity. Conclusions: Overexpression rates of HER-2 in gastric cancer were reported 6.8-34%. Racial differences and different scoring techniques thought to be impact the results. Co-amplification rate of HER-2 and Topo-2A was reported 34% in gastric cancer. In our study HER-2 and Topo-2A overexpression rates were 7.7% and 13.6% respectively and co-amplification of HER-2 with Topo-2A rate was 37.5% is also similar to the other studies. Stages of patients with HER-2 and Topo-2A overexpression were similar to the distribution of the overall patients. While intestinal subtypes showed a higher rate of HER-2 overexpression, the median survival times tend to be shorter in HER-2 positive patients.

Download Full-text

Prognostic value of modified Glasgow Prognostic Score (mGPS) and neutrophil-lymphocyte ration (NLR) after curative resection for gastric cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.4_suppl.295 ◽

2020 ◽

Vol 38 (4_suppl) ◽

pp. 295-295

Author(s):

Yusuke Shimodaira ◽

Sachie Koike ◽

Yusuke Takahashi ◽

Masao Okada ◽

Kaori Hayashibara ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Curative Resection ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Rank Test ◽

Independent Predictive Factor ◽

Gastric Cancer Patients

295 Background: Several biomarkers based on serum chemistry have been reported to be associated with the prognosis of several types of cancers. This retrospective study aimed to investigate the prognostic value of preoperative mGPS and NLR after curative resection for gastric cancer. Methods: A total of 295 patients who underwent curative gastrectomy for primary gastric cancer at our institution from January 2013 to December 2017 were enrolled in this study. The mGPS was calculated by CRP and Alb using standard thresholds ( > 0.5 mg/dL for CRP and < 3.5 g/dL for Alb). The NLR was defined as absolute neutrophil count divided by absolute lymphocyte count. The survival curves of patients stratified by each parameter were plotted by the Kaplan-Meier method and compared by log-rank test. Multivariate Cox proportional hazards regression models were used to select parameters independently correlated with prognosis. Results: The median follow-up time was 36.7 months, and 29 patients died during follow-up. The estimated 5-year survival rate was 83.1%. Results from the univariate analyses showed mGPS2 (CRP > 0.5 mg/dL and Alb < 3.5 g/dL) was associated with poor survival while NLR and NLRc was not (P < 0.001, P = 0.506, and P = 0.423, respectively). In the multivariate analyses, the mGPS2 was identified as an independent predictive factor for OS in gastric cancer patients after curative resection (HR: 2.624; 95% CI: 1.058-6.505; P = 0.037). Conclusions: Preoperative mGPS2 was associated with worse survival after curative resection of gastric cancer patients. Based on our study, those with mPGS2 may be warranted to receive additional therapy or nutritional support to acquire better survival.

Download Full-text

Prevalence and Clinical Implications of Ascites in Gastric Cancer Patients after Curative Surgery

Journal of Clinical Medicine ◽

10.3390/jcm10163557 ◽

2021 ◽

Vol 10 (16) ◽

pp. 3557

Author(s):

Ju-Hee Lee ◽

Sung-Joon Kwon ◽

Mimi Kim ◽

Bo-Kyeong Kang

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Curative Resection ◽

Small Volume ◽

Pelvic Cavity ◽

Clinical Implications ◽

Curative Surgery ◽

Curative Gastrectomy ◽

Gastric Cancer Patients

We aimed to determine the frequency and clinical significance of ascites that developed during the follow-up period in patients who underwent curative resection for gastric cancer. The study included 577 patients with gastric cancer who underwent curative gastrectomy. Among them, 184 showed ascites in postoperative follow-up images. Benign ascites was observed in 131 of 490 patients without recurrence, 48 patients (of 87) with recurrence had malignancy-related ascites, and the remaining 5 patients had ascites only prior to recurrence. In most patients without recurrence (97.7%) and in 50% of patients with malignancy-related ascites, the ascites was small in volume and located in the pelvic cavity at the time that it was first identified. However, with the exception of nine patients, malignancy-related pelvic ascites occurred simultaneously or after obvious recurrence. Of those nine patients who had minimal pelvic ascites before obvious recurrence, only one had a clear association with a malignancy-related ascites. In the multivariate analysis, an age of ≤45 was the only independent risk factor for the occurrence of benign ascites. A small volume of pelvic ascites fluid is common in young gastric cancer patients who do not have recurrence after gastrectomy, regardless of sex. It is rare for ascites to be the first manifestation of recurrence.

Download Full-text

Identifying Factors Affecting Cancer-related Death in Patients with Adenocarcinoma Gastric Cancer; An Analysis in the Presence of Competing Risks

International Journal of Cancer Management ◽

10.5812/ijcm.103402 ◽

2021 ◽

Vol 14 (6) ◽

Author(s):

Malihe Safari ◽

Hossein Mahjub ◽

Habib Esmaeili ◽

Mohamad Abasi ◽

Ghodratollah Roshanaei

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Cancer Progression ◽

Competing Risk ◽

Risk Models ◽

Subdistribution Hazard ◽

Factors Affecting ◽

Competing Risk Models ◽

Gastric Cancer Patients

Background: Adenocarcinoma is the most common type of gastric cancer that has shorter survival than other types of gastric cancer. The death of patients with this type of cancer may be due to the progression of cancer or other related causes. Objectives: The aim of this study is to determine the factors affecting death due to the cancer progression in gastric cancer patients with the diagnosis of adenocarcinoma, using competing risk models. Methods: This retrospective cohort study was performed on 306 gastric cancer patients diagnosed with adenocarcinoma referring to Imam Khomeini clinic in Hamadan from 2002 to 2017. Death due to the cancer progression was considered an interest event and death due to without progression as a competing event. To determine the effect of covariates on hazard, the cause-specific and subdistribution hazard regression models were used. Data analysis was performed, using R3.6.1 software and cmprsk and survival packages. Results: The mean (SD) age of patients was 62.3 (12.5) years and 74.3% were male. The effect of the stage, the number of involved lymphomas, and the type of treatment were significant on the hazard of death due to the disease progression in both cause-specific and subdistribution hazard models. Conclusions: The results showed that most deaths occur in the first 3 years of follow-up. The higher stage and higher number of lymph nodes have increased the hazard of death but supplementary treatment significantly decreased the hazard of death due to cancer progression in adenocarcinoma gastric cancer patients in both competing risk models.

Download Full-text

Polymorphism of MUC1 gene in Vietnamese gastric cancer patients: a case-control study

10.21203/rs.2.14183/v1 ◽

2019 ◽

Author(s):

Lan Thi Ngoc Nguyen ◽

Dzung Thi Ngoc Dang ◽

Van Thanh Ta ◽

Huy Quang Dang ◽

Chuc Van Tran ◽

...

Keyword(s):

Gastric Cancer ◽

Family History ◽

Single Nucleotide Polymorphisms ◽

Cancer Patients ◽

Nucleotide Polymorphisms ◽

Mucin 1 ◽

Single Nucleotide ◽

History Of ◽

Gastric Cancer Patients ◽

Multifactor Regression

Abstract Background Gastric cancer is a malignant type of cancer associated with many factors such as environment, behavior, infection, and genetics, which include Single Nucleotide Polymorphism. A few studies revealed polymorphisms of the Mucin 1 gene have a role and significance as a susceptible factor contributing to gastric cancer. The aim of this research is to evaluate the association between Single Nucleotide Polymorphisms of the Mucin 1 gene and Vietnamese gastric cancer patients.Methods 302 gastric cancer patients and 304 controls were interviewed for social-economic characteristics, smoking and drinking status, personal and family history of gastric diseases. Genotyping was done using polymerase chain reaction-restriction fragment length polymorphism analysis. The association of Single Nucleotide Polymorphisms with gastric cancer was evaluated using multifactor regression models.Results AA genotype for rs4072037 was found to be highly associated with gastric cancer (OR: 2.07 (95% CI: 1.46-2.90). GG genotype for rs2070803 increased the risk of gastric cancer (OR:1.96 (95% CI: 1.37-2.78). These genotypes in combination with other factors such as old age, male gender, alcoholism and personal history of gastric disease also showed an increased risk of having gastric cancer.Conclusions rs4072037 and rs2070803 of Mucin 1 genes are two genotypic risk factors of gastric cancer. Those in combination with other factors such as gender, family history, smoking and drinking habits significantly increase the risk of gastric cancer.

Download Full-text